BioCentury on BioBusiness,
Jazz continues specialty acquisition strategy, but will shift focus to R&D buys
Jazz's big band sound
Monday, May 7, 2012
A 2008 decision to concentrate
on its commercial business has paid off for Jazz Pharmaceuticals Inc.
The company has quadrupled its revenues, reduced its debt and increased its
number of marketed drugs tenfold with two recent acquisitions. Jazz now
plans to use that track record to woo specialty pharmas with R&D stage
Jazz was formed in 2003 to
in-license or acquire assets close to market. By 2008, the company had a pipeline
of Phase II and Phase III programs, but financial constraints and clinical
setbacks caused it to essentially shut down development to focus on growing the
revenues of narcolepsy drug Xyrem sodium oxybate.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]